References
- Wells EM, Dalmau J. Paraneoplastic neurologic disorders in children.
Curr Neurol Neurosci Rep 2011;11:187-94.
- Pranzatelli MR, Slev PR, Tate ED, et al. Cerebrospinal fluid
oligoclonal bands in childhood opsoclonus-myoclonus. Pediatr Neurol
2011;45:27-33.
- Berridge G, Menassa DA, Moloney T, et al. Glutamate receptor δ2 serum
antibodies in pediatric opsoclonus myoclonus ataxia syndrome.
Neurology 2018;91:e714-e723.
- de Alarcon PA, Matthay KK, London WB, et al. Intravenous
immunoglobulin with prednisone and risk-adapted chemotherapy for
children with opsoclonus myoclonus ataxia syndrome associated with
neuroblastoma (ANBL00P3): a randomised, open-label, phase 3 trial.
Lancet Child Adolesc Health 2018;2:25-34.
- Pranzatelli MR. The immunopharmacology of the opsoclonus-myoclonus
syndrome. Clin Neuropharmacol 1996;19:1-47.
- de Graaf MT, de Jongste AH, Kraan J, et al. Boonstra JG, Sillevis
Smitt PA, Gratama JW. Flow cytometric characterization of
cerebrospinal fluid cells. Cytometry B Clin Cytom 2011;80:271-81.
- Ertle F, Behnisch W, Al Mulla NA, et al. Treatment of
neuroblastoma-related opsoclonus-myoclonus-ataxia syndrome with
high-dose dexamethasone pulses. Pediatr Blood Cancer 2008;50:683-7.
- Mitchell WG, Wooten AA, O’Neil SH, et al. Effect of increased
immunosuppression on developmental outcome of opsoclonus myoclonus
syndrome (OMS). J Child Neurol 2015;30:976-82.
- Kitaura K, Yamashita H, Ayabe H, et al. Different somatic
hypermutation levels among antibody subclasses disclosed by a new
next-generation sequencing-based antibody repertoire analysis. Front
Immunol 2017;8:389.
- Gambini C, Conte M, Bernini G, et al. Neuroblastic tumors associated
with opsoclonus-myoclonus syndrome: histological, immunohistochemical
and molecular features of 15 Italian cases. Virchows Arch
2003;442:555-62.
- Pranzatelli MR, Travelstead AL, Tate ED, et al. B- and T-cell markers
in opsoclonus-myoclonus syndrome: immunophenotyping of CSF
lymphocytes. Neurology 2004;62:1526-32.
- Sato Y, Shimoda M, Sota Y, et al. Enhanced humoral immunity in breast
cancer patients with high serum concentration of anti-HER2
autoantibody. Cancer Med 2021;10:1418-1430.
- Katoh H, Komura D, Konishi H, et al. Immunogenetic profiling for
gastric cancers identifies sulfated glycosaminoglycans as major and
functional B cell antigens in human malignancies. Cell Rep
2017;20:1073-1087.
- Pranzatelli MR, Tate ED, Swan JA, et al. B cell depletion therapy for
new-onset opsoclonus-myoclonus. Mov Disord 2010;25:238-42.
- Pranzatelli MR, Tate ED, Travelstead AL, et al. Rituximab (anti-CD20)
adjunctive therapy for opsoclonus-myoclonus syndrome. J Pediatr
Hematol Oncol 2006;28:585-93.
- Patel A, Fischer C, Lin YC, et al. Treatment and revaccination of
children with paraneoplastic opsoclonus-myoclonus-ataxia syndrome and
neuroblastoma: The Memorial Sloan Kettering experience. Pediatr Blood
Cancer 2020;67:e28319.